{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:46:05Z","timestamp":1760150765233,"version":"build-2065373602"},"reference-count":21,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health and Welfare","award":["HI19C0811"],"award-info":[{"award-number":["HI19C0811"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Studies have reported conflicting results on the association between the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and cancer development. We compared the incidence of cancer between patients using RAAS inhibitors and other antihypertensive drugs. This retrospective observational cohort study used data from seven hospitals in Korea that were converted for use in the Observational Medical Outcomes Partnership Common Data Model. A total of 166,071 patients on antihypertensive therapy across the databases of the seven hospitals were divided into two groups according to the use of RAAS inhibitors. The primary outcome was the occurrence of cancer. A total of 166,071 patients across the databases of the seven hospitals was included in the final analysis; 26,650 (16%) were in the RAAS inhibitors group and 139,421 (84%) in the other antihypertensive drugs group. The meta-analysis of the whole cohort showed a lower incidence of cancer occurrence in the RAAS inhibitor group (9.90 vs. 13.28 per 1000 person years; HR, 0.81; 95% confidence interval [CI], 0.75\u20130.88). After propensity-score matching, the RAAS inhibitor group consistently showed a lower incidence of cancer (9.90 vs. 13.28 per 1000 person years; HR, 0.86; 95% CI, 0.81\u20130.91). The patients using RAAS inhibitors showed a lower incidence of cancer compared with those using other antihypertensive drugs. These findings support the association between the use of RAAS inhibitors and cancer occurrence.<\/jats:p>","DOI":"10.3390\/diagnostics12020263","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:37:18Z","timestamp":1642754238000},"page":"263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Cancer: A Population-Based Cohort Study Using a Common Data Model"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-7519","authenticated-orcid":false,"given":"Seung-Hwa","family":"Lee","sequence":"first","affiliation":[{"name":"Rehabilitation and Prevention Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea"},{"name":"Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungchan","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea"},{"name":"Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon 16499, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-3287","authenticated-orcid":false,"given":"Rae Woong","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon 16499, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0861-3576","authenticated-orcid":false,"given":"Seo Jeong","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon 16499, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinseob","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, School of Public Health, Seoul National University, Seoul 03080, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1006-5727","authenticated-orcid":false,"given":"Ji Dong","family":"Sung","sequence":"additional","affiliation":[{"name":"Rehabilitation and Prevention Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-2044","authenticated-orcid":false,"given":"Dae Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon 16499, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwangmo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon 16499, Korea"},{"name":"Center for Health Promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/hr.2009.184","article-title":"Reinventing the ACE inhibitors: Some old and new implications of ACE inhibition","volume":"33","author":"Hanif","year":"2010","journal-title":"Hypertens. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CEJ.0000000000000269","article-title":"The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis","volume":"26","author":"Song","year":"2017","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.phrs.2019.01.037","article-title":"Intriguing relationship between antihypertensive therapy and cancer","volume":"141","author":"Tadic","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","article-title":"Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk","volume":"108","author":"Sipahi","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12094-020-02488-3","article-title":"Renin-angiotensin system and cancer: Epidemiology, cell signaling, genetics and epigenetics","volume":"23","author":"Afsar","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_7","first-page":"467","article-title":"Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) Database into Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM)","volume":"245","author":"You","year":"2017","journal-title":"Stud. Health Technol. Inform."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0093-3619(08)79209-8","article-title":"Association of ACE Inhibitors and Angiotensin Receptor Blockers with Keratinocyte Cancer Prevention in the Randomized VATTC Trial","volume":"2009","author":"Thiers","year":"2009","journal-title":"Year Book Dermatol. Dermatol. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"62545","DOI":"10.18632\/oncotarget.19117","article-title":"Antihypertensive drug use and breast cancer risk: A meta-analysis of observational studies","volume":"8","author":"Ni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cao, L., Zhang, S., Jia, C.M., He, W., Wu, L.T., Li, Y.Q., Wang, W., Li, Z., and Ma, J. (2018). Antihypertensive drugs use and the risk of prostate cancer: A meta-analysis of 21 observational studies. BMC Urol., 18.","DOI":"10.1186\/s12894-018-0318-7"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gomez-Acebo, I., Dierssen-Sotos, T., Palazuelos, C., Perez-Gomez, B., Lope, V., Tusquets, I., Alonso, M.H., Moreno, V., Amiano, P., and Molina de la Torre, A.J. (2016). The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0159672"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","article-title":"Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in Denmark","volume":"92","author":"Friis","year":"2001","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jdv.12921","article-title":"Use of antihypertensive drugs and risk of skin cancer","volume":"29","author":"Schmidt","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1440-1746.2011.06964.x","article-title":"Role of renin-angiotensin system in gastric oncogenesis","volume":"27","author":"Mitsushige","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MPA.0b013e3181c314cd","article-title":"Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells","volume":"39","author":"Gong","year":"2010","journal-title":"Pancreas"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"10284","DOI":"10.1073\/pnas.0900351106","article-title":"AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist","volume":"106","author":"Rhodes","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-5793(01)02377-8","article-title":"Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist","volume":"495","author":"Fujimoto","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","article-title":"Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy","volume":"135","author":"Wilop","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/ije\/dyy120","article-title":"Evaluating large-scale propensity score performance through real-world and synthetic data experiments","volume":"47","author":"Tian","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jama.2017.13836","article-title":"Incidence and Trends of Sepsis in US Hospitals Using Clinical vs. Claims Data, 2009\u20132014","volume":"318","author":"Rhee","year":"2017","journal-title":"JAMA"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/2\/263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:05:03Z","timestamp":1760133903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/2\/263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["diagnostics12020263"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12020263","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2022,1,21]]}}}